The orthobiologics market is anticipated to expand its boundaries at a CAGR of 3.0% during the forecast period. The market holds a share of US$ 6.0 billion in 2023, while it is expected to cross a value of US$ 8.1 billion by 2033.
The orthobiologics market outlook states that the increased healthcare budget is pushing the adoption of advanced healthcare equipment with advancing technology. Furthermore, bone-related disorders & injuries are propelling the growth of the orthobiologics market. The increase in the overall patient tally is likely to impact the market positively. The increased application of viscosupplements for delaying knee replacement and surgeries is also pushing healthcare facilities to adopt orthobiologics products. Along with this, the long physical pain is also pushing end users to adopt technologies that prevent and delay painful surgeries. The rising amount of product introductions is likely to impact the sales of orthobiologics products. Increasing accidents in urban spaces are leading to higher bone disorders and fractures, leading to the adoption of orthobiologics in the healthcare systems.
The advanced integration systems with research and development extensions are creating exciting future opportunities for biological substances that are healing musculoskeletal injuries quickly. The products include bone allograftchevron, soft tissue allograftchevron, and cartilage allograftchevron. Though, orthopedic biologic products work as an optimum treatment solution for knee and shoulder injuries.
| Attributes | Details |
|---|---|
| Orthobiologics Market CAGR (2023 to 2033) | 3.0% |
| Orthobiologics Market Size (2023) | US$ 6.0 billion |
| Orthobiologics Market Size (2033) | US$ 8.1 billion |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Short-term Growth: Growing research and development programs in bone and joints are expected to thrive in the market during the period. This also enhanced the company's engagement in orthobiologics and its product.
Mid-term Growth: Increasing geriatric population with age-related dysfunction to the bone-related system is expected to drive the market growth, as elderly people are more prone to fragility fractures and the incidents of fracture are more likely to increase by 10 to 15 times.
Long-term Growth: Growth is expected in the future for orthobiologics as their acceptance as an alternative treatment of orthopedic issues, and bone-related surgeries gain traction. Furthermore, advanced orthobiologics products are penetrating households with people suffering from long-term orthopedic pain. The restoring orthobiologics market is expected to flourish at a CAGR of 3% between 2023 and 2033.
The increasing geriatric population offers surplus opportunities for the manufacturers of orthobiologics. The crucial root of amputations is diseases related to aging as osteoarthritis, musculoskeletal diseases, spine deformity, etc. Increased incidence of accidents owing to increasing urbanization is also a key factor expected to create numerous opportunities for orthobiologics manufacturers. Elevating surgical procedures also presents growth opportunities for the market.
The increased incidences of trauma cases, lifestyle-related diseases, and other chronic disorders have led to a rise in numerous orthopaedic surgeries at a global level. This growing trend is anticipated to increase the sales of orthobiologics products in the present and forthcoming years.
The emergence of online sales channels and government initiatives bot are contributing to the growth of the market. Manufacturers are focused on creating sales directly through their company’s website to target more customers without the interference of third-party distributors. This enables the manufacturers to eliminate the variation in product pricing owing to the involvement of third-party suppliers.
Principal Consultant
| Regions | Absolute Market Growth |
|---|---|
| United States | US$ 749.0 million |
| United Kingdom | US$ 73.3 million |
| China | US$ 61.2 million |
| Japan | US$ 179.5 million |
| India | US$ 13.6 million |
The United States spends High Capital on Orthopedic Enhancements and Future Solutions.
| Region | Attributes |
|---|---|
| United States Market CAGR (2023 to 2033) | 3.2% |
| United States Market Absolute Doller Growth (US$ million/billion) | US$ 749.0 million |
The United States leads the orthobiologics market in terms of market share, as it is expected to hold a value of US$ 2.8 billion by 2033. Increased healthcare budget, rising per capita income, and advancements in the field of orthopedics are expected to accelerate market growth. The citizens are more likely to choose the alternative treatment than go through surgery. The United States spinal implants and orthobiologics portfolio showcases the positive result of the substitute products and how they help the end user in relieving pain. The region is expected to thrive at a CAGR of 3.2% through 2033.
Latest Innovative Products have Transformed the Future of the Global Orthobiologics Market
| Region | Attributes |
|---|---|
| United Kingdom Market CAGR (2023 to 2033) | 2.5% |
| United Kingdom Market Absolute Doller Growth (US$ million/billion) | US$ 73.3 million |
The United Kingdom increased its healthcare audits along with the soaring frequency of accidents and the geriatric population. These efforts are likely to help the industry boom. Furthermore, the advanced diagnosis and treatment procedures push the United Kingdom market with an expected value of US$ 339.9 million by 2033. The rising awareness of alternative orthopedic treatment fuels the demand for orthobiologics products. The nation is likely to expand at a CAGR of 2.5% through 2033.
| Region | Attributes |
|---|---|
| Indian Market CAGR (2023 to 2033) | 6.6% |
| Indian Market Absolute Doller Growth (US$ million/billion) | US$ 13.6 million |
India is constantly building their healthcare sector along with the adoption of advanced orthobiologic products. Furthermore, the integration of regenerative medicines of orthobiologics with platelet-rich plasma therapy is making India the leading market in terms of CAGR. The thriving Indian market is an outcome of the fusion and the belief system of patients that stick with regenerative medicine and alternative treatment. The market is expected to flourish at a CAGR of 6.6% between 2023 to 2033.
| Segment | Top Product Type |
|---|---|
| Top Sub-segment | Bone Graft Substitute |
| CAGR (2017 to 2022) | 2.9% |
| CAGR (2023 to 2033) | 3.5% |
| Segment | Top End User |
|---|---|
| Top Sub-segment | Hospitals |
| CAGR (2017 to 2022) | 8.5% |
| CAGR (2023 to 2033) | 9.1% |
The bone graft substitute segment in the product type category is expected to dominate the global market in the forecast period. This segment has been a lucrative one since 2012. During the 2012 to 2016 timeline, the bone graft substitute segment reflected high growth opportunities and led the global market. This trend is observed in the current market scenario and is expected to continue over the period of assessment. In 2017, the bone graft substitute segment reached a value of US$ 2,521.6 million, and according to the growth trend exhibited by this segment, it is estimated to reach a market valuation of above US$ 3 billion by the end of 2027. During the forecast period from 2023 to 2033, it is poised to reflect a CAGR of 3.5%. However, the segment flourished at a CAGR of 2.9% between 2017 and 2022.
The bone graft substitute segment is further analyzed and divided into allograft, xenograft, synthetic, and bone morphogenetic protein sub-segments. This is the second leading segment in terms of market value. Allograft and synthetic sub-segments have a notable yet almost equal contribution to the revenue of the parent segment.
The allograft sub-segment reached a valuation of US$ 937.5 million by 2022, leading other sub-segments. However, the synthetic subcategory is poised to grow at a relatively higher rate than allografts in the coming years.
Based on end users, the hospital segment thrives at a CAGR of 9.1% during the forecast period. This growth is attributed to the expansion of hospitals as governments focus more on infrastructure. The higher space and capacity to implement and use orthobiologic products also fuels their consumption of them in hospitals.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The market players are focusing on creating advanced products that provide ease to patients. The research and development programs that deliver products to support the patient in their overall recovery process are another factor competitors focus on. This involves the integration of regenerative medicine, alternative therapies, and bone support products.
Latest Developments:
| Attribute | Details |
|---|---|
| Market Size Value in 2023 | US$ 6 billion |
| Market Size Value in End of Forecast (2033) | US$ 8.1 billion |
| Market Analysis | US$ billion for Value |
| Key Region Covered | North America; Latin America; Europe; Asia Pacific; Middle East & Africa (MEA); Others |
| Key Segments | By Product Type, By End User, By Region |
| Key Companies Profiled | Medtronic (Ireland); Zimmer Biomet; DePuy Synthes (Johnson & Johnson Services, Inc.); Stryker; Anika Therapeutics, Inc.; SeaSpine; Bioventus; RTI Surgical; MTF Biologics; Arthrex, Inc.; Smith & Nephew |
| Report Coverage | Market Forecast, Company Share Analysis, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, and Strategic Growth Initiatives |
| Customization & Pricing | Available upon Request |
The market is valued at US$ 6.0 billion in 2023.
Panasonic, Vishay, and Silicon Labs are top market players.
The pharmaceutical industry is the primary consumer of the orthobiologics market.
The market is estimated to reach US$ 8.1 billion by 2033.
The market trend for orthobiologics is expected to record a CAGR of 3.0% by 2033.
1. Executive Summary | Orthobiologics Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2017 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2017 to 2022
4.2. Current and Future Market Size Value (US$ million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Product Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Product Type, 2017 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Product Type, 2023 to 2033
5.3.1. Bone Growth Stimulators
5.3.1.1. Non-Invasive
5.3.1.2. Invasive
5.3.1.3. Ultrasound
5.3.2. Viscosupplements
5.3.2.1. One Injection
5.3.2.2. Three Injection
5.3.2.3. Five Injection
5.3.3. Bone Graft Substitute
5.3.3.1. Allografts
5.3.3.2. Synthetics
5.3.3.3. Xenografts
5.3.3.4. BMP
5.4. Y-o-Y Growth Trend Analysis By Product Type, 2017 to 2022
5.5. Absolute $ Opportunity Analysis By Product Type, 2023 to 2033
6. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By End User
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By End User, 2017 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User, 2023 to 2033
6.3.1. Hospitals
6.3.2. Ambulatory Surgical Centers
6.3.3. Orthopedic Clinics
6.4. Y-o-Y Growth Trend Analysis By End User, 2017 to 2022
6.5. Absolute $ Opportunity Analysis By End User, 2023 to 2033
7. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Region
7.1. Introduction
7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2017 to 2022
7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
7.3.1. North America
7.3.2. Latin America
7.3.3. Europe
7.3.4. Asia Pacific excluding Japan
7.3.5. Japan
7.3.6. MIDDLE EAST AND AFRICA
7.4. Market Attractiveness Analysis By Region
8. North America Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country
8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022
8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
8.2.1. By Country
8.2.1.1. USA
8.2.1.2. Canada
8.2.2. By Product Type
8.2.3. By End User
8.3. Market Attractiveness Analysis
8.3.1. By Country
8.3.2. By Product Type
8.3.3. By End User
8.4. Key Takeaways
9. Latin America Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. Brazil
9.2.1.2. Mexico
9.2.1.3. Rest of Latin America
9.2.2. By Product Type
9.2.3. By End User
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Product Type
9.3.3. By End User
9.4. Key Takeaways
10. Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Germany
10.2.1.2. UK
10.2.1.3. France
10.2.1.4. Spain
10.2.1.5. Italy
10.2.1.6. Rest of Europe
10.2.2. By Product Type
10.2.3. By End User
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Product Type
10.3.3. By End User
10.4. Key Takeaways
11. Asia Pacific excluding Japan Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. China
11.2.1.2. India
11.2.1.3. Australia & New Zealand
11.2.1.4. Association of Southeast Asian Nations
11.2.1.5. Rest of Asia Pacific excluding Japan
11.2.2. By Product Type
11.2.3. By End User
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Product Type
11.3.3. By End User
11.4. Key Takeaways
12. Japan Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.2. By Product Type
12.2.3. By End User
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Product Type
12.3.3. By End User
12.4. Key Takeaways
13. MIDDLE EAST AND AFRICA Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. GCC Countries
13.2.1.2. South Africa
13.2.1.3. Rest of Middle East & Africa
13.2.2. By Product Type
13.2.3. By End User
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Product Type
13.3.3. By End User
13.4. Key Takeaways
14. Key Countries Market Analysis
14.1. USA
14.1.1. Pricing Analysis
14.1.2. Market Share Analysis, 2022
14.1.2.1. By Product Type
14.1.2.2. By End User
14.2. Canada
14.2.1. Pricing Analysis
14.2.2. Market Share Analysis, 2022
14.2.2.1. By Product Type
14.2.2.2. By End User
14.3. Brazil
14.3.1. Pricing Analysis
14.3.2. Market Share Analysis, 2022
14.3.2.1. By Product Type
14.3.2.2. By End User
14.4. Mexico
14.4.1. Pricing Analysis
14.4.2. Market Share Analysis, 2022
14.4.2.1. By Product Type
14.4.2.2. By End User
14.5. Germany
14.5.1. Pricing Analysis
14.5.2. Market Share Analysis, 2022
14.5.2.1. By Product Type
14.5.2.2. By End User
14.6. UK
14.6.1. Pricing Analysis
14.6.2. Market Share Analysis, 2022
14.6.2.1. By Product Type
14.6.2.2. By End User
14.7. France
14.7.1. Pricing Analysis
14.7.2. Market Share Analysis, 2022
14.7.2.1. By Product Type
14.7.2.2. By End User
14.8. Spain
14.8.1. Pricing Analysis
14.8.2. Market Share Analysis, 2022
14.8.2.1. By Product Type
14.8.2.2. By End User
14.9. Italy
14.9.1. Pricing Analysis
14.9.2. Market Share Analysis, 2022
14.9.2.1. By Product Type
14.9.2.2. By End User
14.10. China
14.10.1. Pricing Analysis
14.10.2. Market Share Analysis, 2022
14.10.2.1. By Product Type
14.10.2.2. By End User
14.11. India
14.11.1. Pricing Analysis
14.11.2. Market Share Analysis, 2022
14.11.2.1. By Product Type
14.11.2.2. By End User
14.12. Australia & New Zealand
14.12.1. Pricing Analysis
14.12.2. Market Share Analysis, 2022
14.12.2.1. By Product Type
14.12.2.2. By End User
14.13. Association of Southeast Asian Nations (ASEAN)
14.13.1. Pricing Analysis
14.13.2. Market Share Analysis, 2022
14.13.2.1. By Product Type
14.13.2.2. By End User
14.14. Japan
14.14.1. Pricing Analysis
14.14.2. Market Share Analysis, 2022
14.14.2.1. By Product Type
14.14.2.2. By End User
14.15. GCC Countries
14.15.1. Pricing Analysis
14.15.2. Market Share Analysis, 2022
14.15.2.1. By Product Type
14.15.2.2. By End User
14.16. South Africa
14.16.1. Pricing Analysis
14.16.2. Market Share Analysis, 2022
14.16.2.1. By Product Type
14.16.2.2. By End User
15. Market Structure Analysis
15.1. Competition Dashboard
15.2. Competition Benchmarking
15.3. Market Share Analysis of Top Players
15.3.1. By Regional
15.3.2. By Product Type
15.3.3. By End User
16. Competition Analysis
16.1. Competition Deep Dive
16.1.1. Medtronic plc
16.1.1.1. Overview
16.1.1.2. Product Portfolio
16.1.1.3. Profitability by Market Segments
16.1.1.4. Sales Footprint
16.1.1.5. Strategy Overview
16.1.1.5.1. Marketing Strategy
16.1.2. NuVasive, Inc.
16.1.2.1. Overview
16.1.2.2. Product Portfolio
16.1.2.3. Profitability by Market Segments
16.1.2.4. Sales Footprint
16.1.2.5. Strategy Overview
16.1.2.5.1. Marketing Strategy
16.1.3. Stryker Corporation
16.1.3.1. Overview
16.1.3.2. Product Portfolio
16.1.3.3. Profitability by Market Segments
16.1.3.4. Sales Footprint
16.1.3.5. Strategy Overview
16.1.3.5.1. Marketing Strategy
16.1.4. Zimmer Biomet Holdings
16.1.4.1. Overview
16.1.4.2. Product Portfolio
16.1.4.3. Profitability by Market Segments
16.1.4.4. Sales Footprint
16.1.4.5. Strategy Overview
16.1.4.5.1. Marketing Strategy
16.1.5. Orthofix International N.V.
16.1.5.1. Overview
16.1.5.2. Product Portfolio
16.1.5.3. Profitability by Market Segments
16.1.5.4. Sales Footprint
16.1.5.5. Strategy Overview
16.1.5.5.1. Marketing Strategy
16.1.6. Anika Therapeutics, Inc.
16.1.6.1. Overview
16.1.6.2. Product Portfolio
16.1.6.3. Profitability by Market Segments
16.1.6.4. Sales Footprint
16.1.6.5. Strategy Overview
16.1.6.5.1. Marketing Strategy
16.1.7. DePuy Synthes
16.1.7.1. Overview
16.1.7.2. Product Portfolio
16.1.7.3. Profitability by Market Segments
16.1.7.4. Sales Footprint
16.1.7.5. Strategy Overview
16.1.7.5.1. Marketing Strategy
16.1.8. Bioventus
16.1.8.1. Overview
16.1.8.2. Product Portfolio
16.1.8.3. Profitability by Market Segments
16.1.8.4. Sales Footprint
16.1.8.5. Strategy Overview
16.1.8.5.1. Marketing Strategy
16.1.9. Arthrex, Inc.
16.1.9.1. Overview
16.1.9.2. Product Portfolio
16.1.9.3. Profitability by Market Segments
16.1.9.4. Sales Footprint
16.1.9.5. Strategy Overview
16.1.9.5.1. Marketing Strategy
16.1.10. SeaSpine Holdings Corporation
16.1.10.1. Overview
16.1.10.2. Product Portfolio
16.1.10.3. Profitability by Market Segments
16.1.10.4. Sales Footprint
16.1.10.5. Strategy Overview
16.1.10.5.1. Marketing Strategy
16.1.11. Sanofi SA
16.1.11.1. Overview
16.1.11.2. Product Portfolio
16.1.11.3. Profitability by Market Segments
16.1.11.4. Sales Footprint
16.1.11.5. Strategy Overview
16.1.11.5.1. Marketing Strategy
16.1.12. Djo Global, Inc.
16.1.12.1. Overview
16.1.12.2. Product Portfolio
16.1.12.3. Profitability by Market Segments
16.1.12.4. Sales Footprint
16.1.12.5. Strategy Overview
16.1.12.5.1. Marketing Strategy
16.1.13. Seikagaku Corporation
16.1.13.1. Overview
16.1.13.2. Product Portfolio
16.1.13.3. Profitability by Market Segments
16.1.13.4. Sales Footprint
16.1.13.5. Strategy Overview
16.1.13.5.1. Marketing Strategy
16.1.14. RTI Surgical, Inc.
16.1.14.1. Overview
16.1.14.2. Product Portfolio
16.1.14.3. Profitability by Market Segments
16.1.14.4. Sales Footprint
16.1.14.5. Strategy Overview
16.1.14.5.1. Marketing Strategy
16.1.15. Heraeus Holding GmbH
16.1.15.1. Overview
16.1.15.2. Product Portfolio
16.1.15.3. Profitability by Market Segments
16.1.15.4. Sales Footprint
16.1.15.5. Strategy Overview
16.1.15.5.1. Marketing Strategy
16.1.16. Fidia Pharma USA Inc.
16.1.16.1. Overview
16.1.16.2. Product Portfolio
16.1.16.3. Profitability by Market Segments
16.1.16.4. Sales Footprint
16.1.16.5. Strategy Overview
16.1.16.5.1. Marketing Strategy
16.1.17. TRB Chemedica International SA
16.1.17.1. Overview
16.1.17.2. Product Portfolio
16.1.17.3. Profitability by Market Segments
16.1.17.4. Sales Footprint
16.1.17.5. Strategy Overview
16.1.17.5.1. Marketing Strategy
16.1.18. Allosource
16.1.18.1. Overview
16.1.18.2. Product Portfolio
16.1.18.3. Profitability by Market Segments
16.1.18.4. Sales Footprint
16.1.18.5. Strategy Overview
16.1.18.5.1. Marketing Strategy
16.1.19. Musculoskeletal Transplant Foundation, Inc.
16.1.19.1. Overview
16.1.19.2. Product Portfolio
16.1.19.3. Profitability by Market Segments
16.1.19.4. Sales Footprint
16.1.19.5. Strategy Overview
16.1.19.5.1. Marketing Strategy
16.1.20. Ito Co., Ltd.
16.1.20.1. Overview
16.1.20.2. Product Portfolio
16.1.20.3. Profitability by Market Segments
16.1.20.4. Sales Footprint
16.1.20.5. Strategy Overview
16.1.20.5.1. Marketing Strategy
17. Assumptions & Acronyms Used
18. Research Methodology
Explore Healthcare Insights
View Reports
Orthobiologics Market
